Black Patients at Higher Risk for Infection, Poor Outcomes From COVID-19 During Cancer

Black Patients at Higher Risk for Infection, Poor Outcomes From COVID-19 During Cancer

Patients with cancer are more likely to contract the COVID-19 coronavirus and experience complications from the infection—and the risk is highest for Black patients, study findings show. Researchers published the report in JAMA Oncology.

Traits That Make You a Great Nurse Also Lead to Success as a Clinical Trials PI

Traits That Make You  a Great Nurse Also Lead to Success as a Clinical Trials PI

Clinical trials are led by a principal investigator (PI) with a research team that may include physicians, nurses, social workers, and other healthcare professionals. PIs can represent a variety of disciplines, and nurse scientists often hold that role.

Racism, Health Inequities, and Unequal Access to Care Are Oncology Nursing Research Priorities

Racism, Health Inequities, and Unequal Access to Care Are Oncology Nursing Research Priorities

Racial inequality persists across the entire healthcare spectrum—from patient disparities to the healthcare workforce’s current makeup and even to the education of the next generation of practitioners. But nurse scientists conducting clinical trials have the opportunity to change that.

CMS Launches Strategy to Drive Health System Transformation

CMS Launches Strategy to Drive Health System Transformation

Under a newly refreshed strategy, the Centers for Medicare and Medicaid Services’ (CMS) Innovation Center is expanding models in the healthcare industry that reduce program costs and improving quality and outcomes for Medicare and Medicaid beneficiaries, the agency announced in an October 2021 white paper.

Nursing Considerations for Adolescent and Young Adult Cancer Survivorship Care

Nursing Considerations for Adolescent and Young Adult Cancer Survivorship Care

Adolescent and young adults (AYAs)—those diagnosed between the ages of 15 and 39—comprise about 5% of all annual cancer diagnoses. The population has unique challenges that must be considered as part of patient-centered survivorship care planning.

Use ClinicalTrials.gov to Find the Right Cancer Research Studies for Your Patients

Use ClinicalTrials.gov to Find the Right Cancer Research Studies for Your Patients

Among the many online resources for identifying cancer clinical trials, including the National Cancer Institute (NCI), NCI-designated cancer centers or academic cancer centers, and drug and biotechnology companies, ClinicalTrials.gov may be the most comprehensive as a one-stop shop for patients and providers to find publicly and privately supported trials for patients.

Oncology Nursing Society Issues a Call to Action for Using Appropriate Genomics Terminology for Safety and Quality

Oncology Nursing Society Issues a Call to Action for Using Appropriate Genomics Terminology for Safety and Quality

The Oncology Nursing Society (ONS) is calling all oncology nurses to become fluent in the ONS Genomics Taxonomy terms and to use them in their practice. Using consistent and correct genomics terminology minimizes confusion and misconceptions and contributes to the high quality and safe delivery of cancer care.

FDA Reports Teligent Pharma’s Worldwide Voluntary Recall of Lidocaine HCl Topical Solution 4%

FDA Reports Teligent Pharma’s Worldwide Voluntary Recall of Lidocaine HCl Topical Solution 4%

On December 7, 2021, the U.S. Food and Drug Administration (FDA) reported Teligent Pharma’s voluntary recall of two lots of lidocaine HCl topical solution 4% in a 50 ml screw cap glass bottle to the user level. The manufacturer’s testing found that the product is super potent based on an out-of-specification result at the 9-month (lot 16345) and 18-month (lot 15594) stability timepoint.

Patients Cope With Intense Emotions After Clinical Trial Withdrawal

Patients Cope With Intense Emotions After Clinical Trial Withdrawal

When withdrawing from a clinical trial, patients experience a spectrum of emotions ranging from regret, urgency, frustration—and trust in their healthcare professionals, like oncology nurses, according to the results of a study published in JAMA Network Open.

Not Eligible for Trials? Expanded Access May Give Patients Options for Investigational Products

Not Eligible for Trials? Expanded Access May Give Patients Options for Investigational Products

The U.S. Food and Drug Administration’s (FDA’s) expanded access program is a pathway for providers to request using an investigational medical product to treat a patient with an immediately life-threatening or serious disease or condition outside of clinical trials when no comparable or satisfactory alternative therapy options are available. FDA’s Project Facilitate, a comprehensive program within FDA’s Oncology Center of Excellence, makes the pathway more accessible by assisting oncology healthcare professionals in submitting single-patient oncology expanded access applications.